Toward novel vaccines and therapies based on negative-strand RNA viruses.
The study of negative-strand RNA viruses has suggested new strategies to produce more attenuated viruses. Reverse genetics has allowed the implementation of the strategies, and new or improved monovalent vaccines are being developed. In addition, recombinant viruses expressing foreign proteins or epitopes have been produced with the aim of developing multivalent vaccines capable of stimulating humoral and cellular immune responses against more than one pathogen. Finally, recombinant viruses that selectively enter cells expressing tumor markers or the HIV envelope protein have been engineered and shown to lyse target cells. Preclinical and clinical trials of improved and multivalent vaccines and therapeutic (oncolytic) viruses are ongoing.
Molecular Medicine Program, Mayo Foundation, 200 1st Street SW, Rochester, MN 55905, USA.
V
V
von Messling
R
R
Cattaneo
D000818:Animals; D005818:Genetic Engineering; D005822:Genetic Vectors; D006801:Humans; D007167:Immunotherapy; D009154:Mutation; D012327:RNA Virus Infections / Q000517:prevention & control / Q000628:therapy*; D012328:RNA Viruses / Q000235:genetics*; D011995:Recombination, Genetic; D022223:Vaccines, Subunit / Q000235:genetics; D014765:Viral Vaccines / Q000235:genetics*
D022223:Vaccines, Subunit; D014765:Viral Vaccines